Standard

Novel cancer stem marker and its applicability for grading primary human gliomas. / Dolgova, Evgeniya V.; Mishinov, Sergey V.; Proskurina, Anastasiya S. и др.

в: Technology in Cancer Research and Treatment, Том 17, 01.01.2018, стр. 1-8.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Dolgova, EV, Mishinov, SV, Proskurina, AS, Potter, EA, Efremov, YR, Bayborodin, SI, Tyrinova, TV, Stupak, VV, Ostatin, AA, Chernykh, ER & Bogachev, SS 2018, 'Novel cancer stem marker and its applicability for grading primary human gliomas', Technology in Cancer Research and Treatment, Том. 17, стр. 1-8. https://doi.org/10.1177/1533034617753812

APA

Dolgova, E. V., Mishinov, S. V., Proskurina, A. S., Potter, E. A., Efremov, Y. R., Bayborodin, S. I., Tyrinova, T. V., Stupak, V. V., Ostatin, A. A., Chernykh, E. R., & Bogachev, S. S. (2018). Novel cancer stem marker and its applicability for grading primary human gliomas. Technology in Cancer Research and Treatment, 17, 1-8. https://doi.org/10.1177/1533034617753812

Vancouver

Dolgova EV, Mishinov SV, Proskurina AS, Potter EA, Efremov YR, Bayborodin SI и др. Novel cancer stem marker and its applicability for grading primary human gliomas. Technology in Cancer Research and Treatment. 2018 янв. 1;17:1-8. doi: 10.1177/1533034617753812

Author

Dolgova, Evgeniya V. ; Mishinov, Sergey V. ; Proskurina, Anastasiya S. и др. / Novel cancer stem marker and its applicability for grading primary human gliomas. в: Technology in Cancer Research and Treatment. 2018 ; Том 17. стр. 1-8.

BibTeX

@article{25af2419fe01427b8630202544acbee8,
title = "Novel cancer stem marker and its applicability for grading primary human gliomas",
abstract = "Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).",
keywords = "CD133, Glioblastoma, Neurosphere, TAMRA-DNA, Tumor-initiating stem cells, Humans, Neoplastic Stem Cells/metabolism, Brain Neoplasms/metabolism, AC133 Antigen, Biomarkers, Tumor, DNA, Neoplasm/genetics, Neoplasm Grading, Fluorescent Antibody Technique, Glioma/genetics, Tumor Cells, Cultured",
author = "Dolgova, {Evgeniya V.} and Mishinov, {Sergey V.} and Proskurina, {Anastasiya S.} and Potter, {Ekaterina A.} and Efremov, {Yaroslav R.} and Bayborodin, {Sergey I.} and Tyrinova, {Tamara V.} and Stupak, {Vyacheslav V.} and Ostatin, {Alexandr A.} and Chernykh, {Elena R.} and Bogachev, {Sergey S.}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2018.",
year = "2018",
month = jan,
day = "1",
doi = "10.1177/1533034617753812",
language = "English",
volume = "17",
pages = "1--8",
journal = "Technology in Cancer Research and Treatment",
issn = "1533-0346",
publisher = "SAGE Publications Inc.",

}

RIS

TY - JOUR

T1 - Novel cancer stem marker and its applicability for grading primary human gliomas

AU - Dolgova, Evgeniya V.

AU - Mishinov, Sergey V.

AU - Proskurina, Anastasiya S.

AU - Potter, Ekaterina A.

AU - Efremov, Yaroslav R.

AU - Bayborodin, Sergey I.

AU - Tyrinova, Tamara V.

AU - Stupak, Vyacheslav V.

AU - Ostatin, Alexandr A.

AU - Chernykh, Elena R.

AU - Bogachev, Sergey S.

N1 - Publisher Copyright: © The Author(s) 2018.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

AB - Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

KW - CD133

KW - Glioblastoma

KW - Neurosphere

KW - TAMRA-DNA

KW - Tumor-initiating stem cells

KW - Humans

KW - Neoplastic Stem Cells/metabolism

KW - Brain Neoplasms/metabolism

KW - AC133 Antigen

KW - Biomarkers, Tumor

KW - DNA, Neoplasm/genetics

KW - Neoplasm Grading

KW - Fluorescent Antibody Technique

KW - Glioma/genetics

KW - Tumor Cells, Cultured

UR - http://www.scopus.com/inward/record.url?scp=85056464567&partnerID=8YFLogxK

U2 - 10.1177/1533034617753812

DO - 10.1177/1533034617753812

M3 - Article

C2 - 29375020

AN - SCOPUS:85056464567

VL - 17

SP - 1

EP - 8

JO - Technology in Cancer Research and Treatment

JF - Technology in Cancer Research and Treatment

SN - 1533-0346

ER -

ID: 17487542